Wellington Shields & Co. LLC decreased its position in Bristol-Myers Squibb (NYSE:BMY) by 1.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 51,415 shares of the biopharmaceutical company’s stock after selling 700 shares during the period. Bristol-Myers Squibb comprises 1.1% of Wellington Shields & Co. LLC’s investment portfolio, making the stock its 18th biggest position. Wellington Shields & Co. LLC’s holdings in Bristol-Myers Squibb were worth $3,189,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in BMY. Fiduciary Planning LLC acquired a new stake in shares of Bristol-Myers Squibb in the third quarter valued at about $25,000. Founders Capital Management acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at about $31,000. Penbrook Management LLC acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at about $34,000. Black Swift Group LLC acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at about $49,000. Finally, HBC Financial Services PLLC grew its position in shares of Bristol-Myers Squibb by 30.3% in the fourth quarter. HBC Financial Services PLLC now owns 800 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 186 shares during the period. 72.41% of the stock is owned by institutional investors.
Several analysts have recently issued reports on the stock. TheStreet upgraded shares of Bristol-Myers Squibb from a “c+” rating to a “b” rating in a research report on Monday, December 7th. Gabelli lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Friday, November 6th. Societe Generale upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $76.00 price target on the stock in a research report on Monday, November 16th. Smith Barney Citigroup boosted their price target on shares of Bristol-Myers Squibb from $73.00 to $77.00 in a research report on Monday, November 30th. Finally, The Goldman Sachs Group upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “conviction-buy” rating in a report on Tuesday, December 15th. Five research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Bristol-Myers Squibb currently has an average rating of “Buy” and an average price target of $73.75.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Wednesday, February 3rd. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.04. Bristol-Myers Squibb had a negative net margin of 0.11% and a positive return on equity of 27.48%. The business had revenue of $11.07 billion during the quarter, compared to analysts’ expectations of $10.74 billion. During the same quarter in the prior year, the business posted $1.22 EPS. The company’s revenue for the quarter was up 39.3% on a year-over-year basis. As a group, equities research analysts predict that Bristol-Myers Squibb will post 6.35 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Monday, February 1st. Stockholders of record on Monday, January 4th were issued a $0.49 dividend. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.45. The ex-dividend date of this dividend was Thursday, December 31st. This represents a $1.96 annualized dividend and a dividend yield of 3.25%. Bristol-Myers Squibb’s dividend payout ratio is presently 41.79%.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. The company's products include Opdivo for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.
Recommended Story: What is a dividend reinvestment plan?
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.